Discover
SKYE
Skye Bioscience, Inc.
0.68
2 x 0.49
2 x 0.90
bid
ask
-
0.02
2.61%
2 @ 04:00 PM
0.69 +0.01 (2.00%)
| Ytd | -9.97% | |
| 1y | -81.95% |
0.68
day range
0.70
0.57
52 week range
4.99
| Open | 0.69 | Prev Close | 0.69 | Low | 0.68 | High | 0.70 | Mkt Cap | 23.73M |
| Vol | 61.33K | Avg Vol | 183.68K | EPS | -1.45 | P/E | N/A | Forward P/E | -2.27 |
| Beta | 1.75 | Short Ratio | 10.06 | Inst. Own | 86.03% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 0.80 | 200-d Avg | 1.20 | 1yr Est | 18.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.26 | -0.22 | 0.04 | 15.38% |
| 2024-08-09 | 2024-06 | -0.2 | -0.2 | N/A | N/A |
| 2024-05-10 | 2024-03 | -0.16 | -0.18 | -0.02 | -12.50% |
| 2024-03-29 | 2023-12 | -0.38 | N/A | N/A | N/A |
| 2023-11-13 | 2023-09 | 0 | -3.17 | N/A | N/A |
| 2023-08-07 | 2023-06 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-09-30 | Scotiabank | Upgrade | Sector Outperform | |
| 2024-09-20 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2024-09-20 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2024-09-10 | JMP Securities | Upgrade | Market Outperform | |
| 2024-09-09 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2024-09-06 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
Profile
Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein coupled receptors. The company is conducting a Phase 2 clinical trial in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy). The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-09-12 | 5AM PARTNERS VII, LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2024-11-17 | ARSENAULT KAITLYN MELANIE | Chief Financial Officer | 166.34K | Sale |
| 2024-11-17 | DHILLON PUNIT S | Chief Executive Officer | 339.17K | Sale |
| 2024-11-17 | DIEP TUAN TU | Officer | 82.26K | Sale |
| 2023-02-21 | EMERALD HEALTH SCIENCES, INC. | Beneficial Owner of more than 10% of a Class of Security | 169.41M | Stock Award(Grant) |
| 2024-11-17 | GRAYSON PAUL A | Director | 259.70K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | 5AM Venture Management, LLC | 9.91M | 26.07M | 35.32% |
| 2024-09-29 | Versant Venture Management, LLC | 2.01M | 5.28M | 7.15% |
| 2024-09-29 | Sphera Funds Management Ltd. | 1.56M | 4.11M | 5.57% |
| 2024-09-29 | Baker Bros. Advisors, LP | 1.43M | 3.77M | 5.11% |
| 2024-09-29 | Altium Capital Management, LP | 1.32M | 3.46M | 4.69% |
| 2024-09-29 | Blackrock Inc. | 1.19M | 3.14M | 4.25% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 477.10K | 1.25M | 1.70% |
| 2024-10-30 | iShares Russell 2000 ETF | 446.81K | 1.18M | 1.59% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 249.75K | 656.85K | 0.89% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 176.10K | 463.14K | 0.63% |
| 2024-10-30 | AdvisorShares Trust-AdvisorShares Pure Cannabis ETF | 160.00K | 420.80K | 0.57% |
| 2024-10-30 | iShares Russell 2000 Value ETF | 136.82K | 359.83K | 0.49% |
Split
| Split | Date |
|---|---|
| 1 : 250 | 2023-09-08 |